Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
نویسندگان
چکیده
Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance.
منابع مشابه
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2
Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequently mutated in acute myeloid leukaemia (AML), low-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS). For AML, low-grade glioma and CC, mutant IDH status is associated with a DNA hypermethylation phenotype, implicating altered epigenome dynamics in the aetiology of these cancers. Here we show that the IDH variants in CS are also...
متن کاملHighlights and Selected Abstracts from SNO 2014
No. AT-13: “R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: Results by histologic type” was presented by Jan Buckner. This presentation expanded on an earlier announcement at ASCO in June 2014 which showed that the combination of radiotherapy (RT) and PCV (procarbazine, CCNU and vincristine) prolonged both PFS and O...
متن کاملMolecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) and concomitantly produce reduced NADPH from NADP(+) Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its n...
متن کاملDoes mIDH Inhibitors is a Promising Therapy?
IDH are family of enzymes that comprises three proteins, IDH1, IDH2 and IDH3. IDH1 is located in the cytoplasm while IDH2 and IDH3 are located in the mitochondria [1,2]. The IDHs are tricycle carboxylic acid cycle enzymes which convert isocitrate to α-KG via oxidative decarboxylation, producing NADPH (IDH1 and 2) and NADH (IDH3) [3]. IDH proteins are involved in diverse cellular processes inclu...
متن کاملIDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
The recent identification of IDH mutations in gliomas and several other cancers suggests that this pathway is involved in oncogenesis; however effector functions are complex and yet incompletely understood. To study the regulatory effects of IDH on hypoxia-inducible-factor 1-alpha (HIF1A), a driving force in hypoxia-initiated angiogenesis, we analyzed mRNA expression profiles of 288 glioma pati...
متن کامل